Enhanced rifampicin delivery to alveolar macrophages by solid lipid nanoparticles

The present study aimed at developing a drug delivery system targeting the densest site of tuberculosis infection, the alveolar macrophages (AMs). Rifampicin (RFP)-loaded solid lipid nanoparticles (RFP-SLNs) with an average size of 829.6 ± 16.1 nm were prepared by a modified lipid film hydration method. The cytotoxicity of RFP-SLNs to AMs and alveolar epithelial type II cells (AECs) was examined using MTT assays. The viability of AMs and AECs was above 80 % after treatment with RFP-SLNs, which showed low toxicity to both AMs and AECs. Confocal Laser Scanning Microscopy was employed to observe the interaction between RFP-SLNs and both AMs and AECs. After incubating the cells with RFP-SLNs for 2 h, the fluorescent intensity in AMs was more and remained longer (from 0.5 to 12 h) when compared with that in AECs (from 0.5 to 8 h). In vitro uptake characteristics of RFP-SLNs in AMs and AECs were also investigated by detection of intracellular RFP by High performance liquid chromatography. Results showed that RFP-SLNs delivered markedly higher RFP into AMs (691.7 ng/mg in cultured AMs, 662.6 ng/mg in primary AMs) than that into AECs (319.2 ng/mg in cultured AECs, 287.2 ng/mg in primary AECs). Subsequently, in vivo delivery efficiency and the selectivity of RFP-SLNs were further verified in Sprague–Dawley rats. Under pulmonary administration of RFP-SLNs, the amount of RFP in AMs was significantly higher than that in AECs at each time point. Our results demonstrated that solid lipid nanoparticles are a promising strategy for the delivery of rifampicin to alveolar macrophages selectively.

[1]  J. Crofton.  Drug Treatment of Tuberculosis , 1960, British medical journal.

[2]  R. Pallanza,et al.  Rifampicin: a new rifamycin. II. Laboratory studies on the antituberculous activity and preliminary clinical observations. , 1967, Arzneimittel-Forschung.

[3]  P. D. Hart,et al.  RESPONSE OF CULTURED MACROPHAGES TO MYCOBACTERIUM TUBERCULOSIS, WITH OBSERVATIONS ON FUSION OF LYSOSOMES WITH PHAGOSOMES , 1971, The Journal of experimental medicine.

[4]  J. Edelson,et al.  Alkaline phosphatase: a marker of alveolar type II cell differentiation. , 1988, The American review of respiratory disease.

[5]  M. Post,et al.  Histochemical and immunocytochemical identification of alveolar type II epithelial cells isolated from fetal rat lung. , 1988, The American review of respiratory disease.

[6]  R. Beelen,et al.  Novel isolation and purification method permitting functional cytotoxicity studies of macrophages from milky spots in the greater omentum. , 1995, Journal of immunological methods.

[7]  A. Aderem,et al.  Mechanisms of phagocytosis. , 1996, Current opinion in immunology.

[8]  A. Aderem,et al.  Mechanisms of phagocytosis in macrophages. , 1999, Annual review of immunology.

[9]  J. Pieters,et al.  A Coat Protein on Phagosomes Involved in the Intracellular Survival of Mycobacteria , 1999, Cell.

[10]  R. Panchagnula,et al.  Determination of rifampicin and its main metabolite in plasma and urine in presence of pyrazinamide and isoniazid by HPLC method. , 1999, Journal of pharmaceutical and biomedical analysis.

[11]  James C. Sacchettini,et al.  Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase , 2000, Nature.

[12]  G. Bothamley.  Drug Treatment for Tuberculosis during Pregnancy , 2001, Drug safety.

[13]  T. Zahrt.  Molecular mechanisms regulating persistent Mycobacterium tuberculosis infection. , 2003, Microbes and infection.

[14]  Sandra L. Schmid,et al.  Regulated portals of entry into the cell , 2003, Nature.

[15]  Jiwang Chen,et al.  Isolation of highly pure alveolar epithelial type I and type II cells from rat lungs , 2004, Laboratory Investigation.

[16]  Vojo Deretic,et al.  Cell biology of mycobacterium tuberculosis phagosome. , 2004, Annual review of cell and developmental biology.

[17]  R. Pandey,et al.  Oral solid lipid nanoparticle-based antitubercular chemotherapy. , 2005, Tuberculosis.

[18]  Liem Nguyen,et al.  The Trojan horse: survival tactics of pathogenic mycobacteria in macrophages. , 2005, Trends in cell biology.

[19]  H. Junginger,et al.  Non-invasive pulmonary aerosol delivery in mice by the endotracheal route. , 2005, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[20]  R. Pandey,et al.  Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. , 2005, Tuberculosis.

[21]  L. Yahia,et al.  Therapeutic potential of nanoparticulate systems for macrophage targeting. , 2005, Biomaterials.

[22]  T. Seki,et al.  Influence of particle size on drug delivery to rat alveolar macrophages following pulmonary administration of ciprofloxacin incorporated into liposomes , 2006, Journal of drug targeting.

[23]  T. Seki,et al.  Uptake characteristics of liposomes by rat alveolar macrophages: influence of particle size and surface mannose modification , 2007, The Journal of pharmacy and pharmacology.

[24]  G. Soma,et al.  Optimum conditions for efficient phagocytosis of rifampicin-loaded PLGA microspheres by alveolar macrophages. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[25]  T. Seki,et al.  Efficient drug targeting to rat alveolar macrophages by pulmonary administration of ciprofloxacin incorporated into mannosylated liposomes for treatment of respiratory intracellular parasitic infections. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[26]  J. M. Lanao,et al.  Delivery systems to increase the selectivity of antibiotics in phagocytic cells. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[27]  S. Kawakami,et al.  Efficient targeting to alveolar macrophages by intratracheal administration of mannosylated liposomes in rats. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[28]  C. Lehr,et al.  Relevance of the colloidal stability of chitosan/PLGA nanoparticles on their cytotoxicity profile. , 2009, International journal of pharmaceutics.

[29]  Roel P F Schins,et al.  Evaluation of cytotoxic effects and oxidative stress with hydroxyapatite dispersions of different physicochemical properties in rat NR8383 cells and primary macrophages. , 2009, Toxicology in vitro : an international journal published in association with BIBRA.

[30]  Xun Sun,et al.  Inhalable Microparticles as Carriers for Pulmonary Delivery of Thymopentin-Loaded Solid Lipid Nanoparticles , 2010, Pharmaceutical Research.

[31]  H. Terada,et al.  The behavior of PLGA microspheres containing rifampicin in alveolar macrophages. , 2010, Colloids and surfaces. B, Biointerfaces.

[32]  G. Soma,et al.  Delivery of rifampicin-PLGA microspheres into alveolar macrophages is promising for treatment of tuberculosis. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[33]  Cui Tang,et al.  Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. , 2010, Biomaterials.

[34]  J. Keane,et al.  Cellular targeting and trafficking of drug delivery systems for the prevention and treatment of MTb. , 2011, Tuberculosis.

[35]  K. Natarajan,et al.  Innate immune responses to M. tuberculosis infection. , 2011, Tuberculosis.

[36]  Zhang Zhi-rong.  Preparation of Rifampicin-solid lipid nanoparticles and evaluation of their cell specificity , 2011 .